HOME >> MEDICINE >> NEWS
Defibrillators may improve survival in non-ischemic cardiomyopathy

Research from Northwestern University suggests that implantable cardioverter defibrillators (ICDs) can improve the survival rate of people who have a weakened heart muscle caused by factors unrelated to coronary artery disease a condition known as non-ischemic cardiomyopathy. Previous studies showed that people whose heart muscle had been weakened as a result of coronary artery disease (ischemic cardiomyopathy) could benefit from ICDs. This research is among the first to indicate that the approximately 200,000 other Americans who suffer from this condition may also benefit.

An ICD is a small device implanted under the skin near the collarbone and connected to the heart with insulated wires called leads. ICDs deliver shocks and other electrical therapies to the ventricles to stop ventricular tachyarrhythmias (abnormally fast heart rhythms originating in the heart's lower chambers).

Initial results from the DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) ICD were presented today at the American Heart Association's Scientific Sessions 2003 conference in Orlando, Florida by principal investigator Alan Kadish, M.D., Chester D. and Deborah M. Cooley Professor of Medicine from Feinberg School of Medicine at Northwestern University in Chicago.

The DEFINITE study, initiated in May 1998, followed 458 participants at 48 medical centers in the United States and Israel. Participants were randomized into two groups -- one receiving standard heart failure drug therapy (control group) and the other receiving drug therapy plus an implant of a St. Jude Medical ICD. The goal was to evaluate whether the ICDs offered an overall survival benefit to those who received them.

During the study, overall mortality at two years was 13.8 percent in the standard therapy (control) group versus 8.1 percentin the ICD group. Though these results did not reach the level of statistical significance defined in the study protocol, they do show
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
11-Nov-2003


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. New technique shows promise for improved straightening of crooked nose
3. Balance and better interactions between primary-care and specialist physicians improve US health
4. Cornea transplants can be improved
5. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
6. New treatment options for some difficult cancers improve survival and quality of life
7. New substance that improves the photodetection of bladder cancer gains market approval
8. Most advanced CT scanner improves imaging of heart, avoids need for surgical inspection
9. Increasing physician volume requirement could improve mammogram accuracy, study concludes
10. Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke
11. OHSU scientists develop MRI approach to improve breast cancer detection

Post Your Comments:
(Date:6/29/2015)... CA (PRWEB) , ... June 29, 2015 , ... ... and imprinted accessories, is offering discounted pricing on all purchases that include branding. ... foundation of a brand is the logo. The website, packaging and promotional materials, all ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... People across the country give their coworkers and ... part of our culture. , But, how often do coworkers donate “life” to the ... a simple one. , “Dawna (Wright-Thompson) told me her husband was on a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
Cached News: